Use of Adjunctive Corticosteroid With Antivascular Endothelial Growth Factor Agents in the Treatment of Choroidal Neovascular Membrane Associated With Presumed Ocular Histoplasmosis.
| Autor: | Labriola LT; Southwest Pennsylvania Eye Center Washington, PA, USA.; Sewickley Eye Group, Sewickley, PA, USA., Vangipuram G; The Retina Institute, Saint Louis, MO, USA., Zarnegar A; Sewickley Eye Group, Sewickley, PA, USA., Tsipursky M; Retina, Carle Foundation Hospital, Champaign, IL, USA., Besecker J; Saint Joseph's University, Philadelphia, PA, USA., Almasov A; Prairie Education and Research Cooperative, Springfield, IL, USA., Garwood KC; Saint Joseph's University, Philadelphia, PA, USA., Blinder KJ; The Retina Institute, Saint Louis, MO, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of vitreoretinal diseases [J Vitreoretin Dis] 2023 Oct 12; Vol. 7 (6), pp. 510-520. Date of Electronic Publication: 2023 Oct 12 (Print Publication: 2023). |
| DOI: | 10.1177/24741264231201778 |
| Abstrakt: | Purpose: To evaluate the impact of combination treatment of antivascular endothelial growth factor (anti-VEGF) intravitreal injections and corticosteroids in patients with choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis syndrome (POHS). Methods: A retrospective multicenter study was conducted in a cohort from Illinois and Missouri. Patients were identified over an 8-year period, and data were evaluated over a 1-year study window commencing with treatment initiation. Group 1 included patients treated with intravitreal injections of anti-VEGF, and group 2 included those who received intravitreal injections of anti-VEGF and adjuvant corticosteroids. Optical coherence tomography (OCT) measurements and increases in Early Treatment Diabetic Retinopathy Study (ETDRS) letter score were compared between each group. Results: Using the method of last visit carried forward, the visual acuity (VA) in group 2 was 6.42 ETDRS letters better than the VA in group 1 at the final assessment. Patients in group 2 had a mean ETDRS letter gain of 21.50 ( P = .06) from the initial baseline vision. The average amount of decrease in OCT central subfield thickness compared with baseline was lower in group 1 (80.9 ± 129.8 µm) vs group 2 (102.8 ± 90.40 µm) at the 1-year follow-up visit ( P = .25). Conclusions: Approved treatment of CNV secondary to POHS is limited. Adjuvant corticosteroid treatment in patients with CNV secondary to POHS may provide better long-term vision and OCT outcomes than anti-VEGF alone and may offer an additional therapy option for these patients. Competing Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. (© The Author(s) 2023.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|